Irrus Investments' Portfolio

Sigyn Therapy is a patent-pending blood purification technology to mitigate Cytokine Storm Syndrome through the broad-spectrum depletion of life-threatening inflammatory targets from the entire bloodstream.

ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders.

AniV8 (pronounced An-i-vate) is a company designed to become the leading developer of clinical sensor technology recommended by veterinarians to diagnose and monitor common animal disease states.

Sedana medical, a Swedish company, are the developers of the AnaConDa (Anaesthetic Conserving Device) which is an anaesthetic delivery system developed for the administration of volatile anaesthetics such as Isoflurane or Sevoflurane to invasively ventilated patients.

Developer of medical devices designed to improve the outcome of cancer treatment. The company's technology has a unique IP that facilitates for painless delivery of electroporation energy endoscopically which greatly facilitates cancer treatment, enabling physicians to target tumors located anywhere on the body.

CroíValve has developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation.

Deciphex is developing digital pathology software applications, for clinical and toxicologic pathology, that improve productivity and help pathologists focus on the critical content.

HookeBio - The company specializes in microfluidic technology development for high throughput combinatorial drug screening.

Longboat Clinical - In the complex world of clinical development, Longboat's cloud-based site and patient engagement platform empowers clinical trial site staff and patients to do the right thing at the right time, from patient recruitment through to study closeout.

AventaMed develops innovative medical devices which simplify surgery, allowing procedures to move out of the Operating Room and into new sites of service, such as the clinic or doctor’s office.

Nexvet, a biologic therapeutics company, develop a pipeline of monoclonal antibody (mAb) therapies for companion animals in pain and other therapeutic areas.

Sublimity Therapeutics / Sigmoid’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases and disorders.